- Conditions
- Glucosephosphate Dehydrogenase Deficiency, Hyperbilirubinemia, Hemolytic Disease of Newborn
- Interventions
- tin mesoporphyrin
- Drug
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- 0 Years to 24 Hours
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 817–840
of 3,541
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Fathers, Mhealth, Mobile Health, Nuclear Family
- Interventions
- Text4Father
- Behavioral
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Hospitalized Neonates and Infants, Expected to Require Parenteral Nutrition for 28 Days
- Interventions
- Smoflipid 20% (investigational lipid for parenteral nutrition), Intralipid® 20%
- Drug
- Lead sponsor
- Fresenius Kabi
- Industry
- Eligibility
- 0 Weeks and older
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 13
- States / cities
- Palo Alto, California • San Diego, California • New Haven, Connecticut + 8 more
- Conditions
- Single Sided Deafness, Unilateral Deafness, Hearing Loss, Unilateral, Hearing Loss, Congenital Hearing Loss, Deafness One Ear
- Interventions
- Cochlear Implant
- Device
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 7 Months to 71 Months
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2030
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Cystic Fibrosis
- Interventions
- QR-010, Placebo
- Drug
- Lead sponsor
- ProQR Therapeutics
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Palo Alto, California • Chicago, Illinois + 8 more
- Conditions
- Atopic Dermatitis (AD), Asthma
- Interventions
- dupilumab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 581 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Tuberous Sclerosis Complex
- Interventions
- Not listed
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 3 Months to 12 Months
- Enrollment
- 166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Los Angeles, California • Boston, Massachusetts + 2 more
- Conditions
- Individual, Category, and No-label Conditions
- Interventions
- Effects of shared book reading: Labels
- Behavioral
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 5 Months to 65 Years
- Enrollment
- 146 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Total Parenteral Nutrition-induced Cholestasis
- Interventions
- Omegaven, Omegaven
- Dietary Supplement · Drug
- Lead sponsor
- Pediatrix
- Other
- Eligibility
- 14 Days to 2 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Mucopolysaccharidosis II
- Interventions
- Not listed
- Lead sponsor
- REGENXBIO Inc.
- Industry
- Eligibility
- Male only
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia
- Interventions
- Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Calaspargase Pegol, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, Echocardiography Test, FDG-Positron Emission Tomography, Leucovorin, Levoleucovorin, Lumbar Puncture, Magnetic Resonance Imaging, Mercaptopurine, Methotrexate, Methylprednisolone, Multigated Acquisition Scan, Prednisolone, Prednisone, Therapeutic Hydrocortisone, Thioguanine, Venetoclax, Vincristine
- Drug · Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 365 Days
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 115
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 100 more
- Conditions
- Premature Birth of Newborn
- Interventions
- Family Integrated Care
- Behavioral
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- Up to 33 Weeks
- Enrollment
- 347 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 6
- States / cities
- Fresno, California • La Jolla, California • Oakland, California + 3 more
- Conditions
- Complex Congenital Heart Defect
- Interventions
- Not listed
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 1 Day to 30 Days
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Cystic Fibrosis
- Interventions
- Tele-coaching
- Behavioral
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 14 Years to 25 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 6
- States / cities
- Palo Alto, California • Denver, Colorado • Chicago, Illinois + 3 more
- Conditions
- Biliary Atresia
- Interventions
- Not listed
- Lead sponsor
- Arbor Research Collaborative for Health
- Other
- Eligibility
- 6 Months to 20 Years
- Enrollment
- 1,265 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2029
- U.S. locations
- 15
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 12 more
- Conditions
- Anxiety Fear, Prenatal Depression, Infant, Low Birth Weight, Preterm Birth, Maternal
- Interventions
- Mentors Offering Maternal Support (M-O-M-S)
- Behavioral
- Lead sponsor
- University of the Incarnate Word
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,717 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2022
- U.S. locations
- 3
- States / cities
- San Diego, California • San Antonio, Texas • Tacoma, Washington
- Conditions
- Paramyxoviridae Infections, Virus Diseases
- Interventions
- rHPIV3cp45, rHPIV3cp45 placebo
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Months to 36 Months
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2011
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Seattle, Washington
- Conditions
- HIV Infections
- Interventions
- Infant Formula
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 1 Day to 17 Days
- Enrollment
- 2,400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Ends 2005
- U.S. locations
- 62
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 46 more
- Conditions
- Pneumonia, Pneumocystis Carinii, HIV Infections
- Interventions
- Atovaquone
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 1 Month to 12 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1996
- U.S. locations
- 5
- States / cities
- San Francisco, California • Chicago, Illinois • New Orleans, Louisiana + 2 more
- Conditions
- Hypoglycemia, Infant, Small for Gestational Age, Premature Birth of Newborn, Fetal Macrosomia, Intrauterine Growth Restriction, Complication of Prematurity, Neonatal Hypoglycemia
- Interventions
- 40% Dextrose gel
- Dietary Supplement
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 0 Hours to 1 Hour
- Enrollment
- 236 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Bronchopulmonary Dysplasia, Neurally Adjusted Ventilatory Assist, Mechanical Ventilation
- Interventions
- NAVA, CMV
- Device
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- Up to 24 Months
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania • Providence, Rhode Island
- Conditions
- Respiratory Syncytial Viruses
- Interventions
- ABRYSVO Vaccination
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 0 Months to 6 Months
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Persistent Infection, Cystic Fibrosis
- Interventions
- CMTX-101, Placebo
- Drug
- Lead sponsor
- Clarametyx Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Palo Alto, California • San Franciso, California + 20 more
- Conditions
- Nicotine Dependence
- Interventions
- tobacco abstinent contingent, non-contingent, control
- Behavioral
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland